Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant

J Clin Apher. 1999;14(3):154-6. doi: 10.1002/(sici)1098-1101(1999)14:3<154::aid-jca9>3.0.co;2-k.

Abstract

EBV-associated lymphoproliferative disorders (EBV-LPD) are a significant problem after hemopoietic stem cell transplantation from unrelated donors or mismatched family members. Risk factors include T-cell depletion, MHC mismatch, and intensity of immunosuppression. New therapeutic strategies involve cellular immunotherapy approaches and both donor T-cells and EBV-specific cytotoxic T lymphocytes (CTLs) have proven to be effective therapies. EBV-specific CTL has also proved to have a major impact on the incidence of this complication when used prophylactically.

Publication types

  • Review

MeSH terms

  • Antibody Specificity
  • Bone Marrow Transplantation*
  • Herpesvirus 4, Human / immunology*
  • Humans
  • Lymphoma / immunology
  • Lymphoma / therapy
  • Lymphoma / virology*
  • T-Lymphocytes, Cytotoxic / immunology*
  • Transplantation Immunology*